关注
Oleksandr Sverdlov
Oleksandr Sverdlov
Statistical Scientist, Novartis
在 novartis.com 的电子邮件经过验证
标题
引用次数
引用次数
年份
Handling covariates in the design of clinical trials
WF Rosenberger, O Sverdlov
Statistical Science 23 (3), 404-419, 2008
1932008
Digital therapeutics: an integral component of digital innovation in drug development
O Sverdlov, J Van Dam, K Hannesdottir, T Thornton‐Wells
Clinical Pharmacology & Therapeutics 104 (1), 72-80, 2018
1562018
Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral γ-secretase inhibitor BMS-708163 (Avagacestat): tolerability profile …
G Tong, JS Wang, O Sverdlov, SP Huang, R Slemmon, R Croop, ...
Clinical therapeutics 34 (3), 654-667, 2012
922012
Adaptive randomization for clinical trials
WF Rosenberger, O Sverdlov, F Hu
Journal of biopharmaceutical statistics 22 (4), 719-736, 2012
812012
Pharmacodynamics of selective inhibition of γ-secretase by avagacestat
CF Albright, RC Dockens, JE Meredith, RE Olson, R Slemmon, KA Lentz, ...
Journal of Pharmacology and Experimental Therapeutics 344 (3), 686-695, 2013
782013
A roadmap to using randomization in clinical trials
VW Berger, LJ Bour, K Carter, JJ Chipman, CC Everett, N Heussen, ...
BMC medical research methodology 21, 1-24, 2021
552021
A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects
R Dockens, JS Wang, L Castaneda, O Sverdlov, SP Huang, R Slemmon, ...
Clinical pharmacokinetics 51, 681-693, 2012
552012
Effects of single doses of avagacestat (BMS-708163) on cerebrospinal fluid Aβ levels in healthy young men
G Tong, L Castaneda, JS Wang, O Sverdlov, SP Huang, R Slemmon, ...
Clinical drug investigation 32, 761-769, 2012
472012
Modern adaptive randomized clinical trials: statistical and practical aspects
O Sverdlov
CRC Press, 2015
462015
On recent advances in optimal allocation designs in clinical trials
O Sverdlov, WF Rosenberger
Journal of Statistical Theory and Practice 7, 753-773, 2013
442013
Optimal response‐adaptive randomized designs for multi‐armed survival trials
O Sverdlov, Y Tymofyeyev, WK Wong
Statistics in medicine 30 (24), 2890-2910, 2011
442011
Adaptive clinical trial designs for phase I cancer studies
O Sverdlov, WK Wong, Y Ryeznik
332014
Utility of covariate-adjusted response-adaptive randomization in survival trials
O Sverdlov, WF Rosenberger, Y Ryeznik
Statistics in Biopharmaceutical Research 5 (1), 38-53, 2013
282013
An overview of healthcare data analytics with applications to the COVID-19 pandemic
Z Fei, Y Ryeznik, O Sverdlov, CW Tan, WK Wong
IEEE Transactions on Big Data 8 (6), 1463-1480, 2021
242021
A comparative study of restricted randomization procedures for multiarm trials with equal or unequal treatment allocation ratios
Y Ryeznik, O Sverdlov
Statistics in Medicine 37 (21), 3056-3077, 2018
242018
A study of novel exploratory tools, digital technologies, and central nervous system biomarkers to characterize unipolar depression
O Sverdlov, J Curcic, K Hannesdottir, L Gou, V De Luca, F Ambrosetti, ...
Frontiers in Psychiatry 12, 640741, 2021
232021
Citalopram for acute and preventive efficacy in bipolar depression (CAPE-BD): a randomized, double-blind, placebo-controlled trial
SN Ghaemi, EA Whitham, PA Vohringer, SA Barroilhet, A Amerio, ...
The Journal of Clinical Psychiatry 82 (1), 6067, 2021
222021
A smartphone-based intervention as an adjunct to standard-of-care treatment for schizophrenia: randomized controlled trial
SN Ghaemi, O Sverdlov, J van Dam, T Campellone, R Gerwien
JMIR formative research 6 (3), e29154, 2022
212022
Implementing unequal randomization in clinical trials with heterogeneous treatment costs
O Sverdlov, Y Ryeznik
Statistics in Medicine 38 (16), 2905-2927, 2019
212019
Randomization in clinical trials: can we eliminate bias?
O Sverdlov, WF Rosenberger
202013
系统目前无法执行此操作,请稍后再试。
文章 1–20